Advisor Resource Council Purchases Shares of 79,070 Biotricity, Inc. (NASDAQ:BTCY)

Advisor Resource Council purchased a new stake in shares of Biotricity, Inc. (NASDAQ:BTCYFree Report) in the 1st quarter, according to the company in its most recent 13F filing with the SEC. The firm purchased 79,070 shares of the company’s stock, valued at approximately $117,000. Advisor Resource Council owned approximately 0.84% of Biotricity at the end of the most recent reporting period.

Biotricity Stock Up 3.3 %

NASDAQ BTCY traded up $0.03 during trading on Thursday, hitting $0.79. 62,313 shares of the stock traded hands, compared to its average volume of 48,681. The company has a market capitalization of $7.40 million, a P/E ratio of -0.59 and a beta of 1.39. The firm has a 50-day simple moving average of $1.07 and a 200-day simple moving average of $1.12. Biotricity, Inc. has a 12-month low of $0.70 and a 12-month high of $3.75.

Biotricity (NASDAQ:BTCYGet Free Report) last released its quarterly earnings results on Thursday, June 27th. The company reported ($0.47) earnings per share for the quarter, missing the consensus estimate of ($0.36) by ($0.11). The business had revenue of $3.18 million during the quarter, compared to analyst estimates of $3.20 million. As a group, research analysts predict that Biotricity, Inc. will post -0.43 EPS for the current fiscal year.

About Biotricity

(Free Report)

Biotricity, Inc, a medical technology company, provides biometric data monitoring solutions in the United States. The company focuses on delivery of remote monitoring solutions to medical, healthcare, and consumer markets, including diagnostic and post-diagnostic solutions for lifestyle and chronic illnesses.

Featured Articles

Want to see what other hedge funds are holding BTCY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Biotricity, Inc. (NASDAQ:BTCYFree Report).

Receive News & Ratings for Biotricity Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biotricity and related companies with MarketBeat.com's FREE daily email newsletter.